Résultats de la recherche
10
Tout
Annovis to Host Patients’ Live Forum on February 27, 2025
19 févr. 2025 08h30 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
07 févr. 2025 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
05 févr. 2025 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
04 févr. 2025 16h31 HE
|
Annovis Bio, Inc.
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
03 févr. 2025 06h22 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio, Inc. Announces Proposed Public Offering
31 janv. 2025 20h14 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
05 déc. 2024 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is...
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
11 nov. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
31 oct. 2024 08h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
22 oct. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies...